Literature DB >> 10594859

Alternative medicine use in patients with localized prostate carcinoma treated with curative intent.

M C Lippert1, R McClain, J C Boyd, D Theodorescu.   

Abstract

BACKGROUND: Alternative medicine therapies are estimated to be used by 7-64% of cancer patients but up to 72% do not inform their physician. To the authors' knowledge little useful information is available regarding the prevalence of alternative medicine use by patients with prostate carcinoma. Thus, the authors attempted to evaluate the prevalence of alternative medicine use by prostate carcinoma patients treated with curative intent by either radical prostatectomy, brachytherapy alone, or a combination of brachytherapy and external radiation therapy.
METHODS: Between January 1997 and May 1998, 234 men with clinically localized prostate carcinoma underwent radical prostatectomy (54 patients) or brachytherapy (180 patients) with (74 patients) or without (106 patients) external beam radiation therapy. In July 1998 a questionnaire was mailed to all patients comprised of multiple questions regarding alternative medicine use to which 190 patients (81%) responded. The overall prevalence and types of alternative medicine therapies used were assessed and the relation between age at procedure, pretreatment prostate specific antigen level, clinical stage, pretreatment Gleason score, and type of treatment with the use of alternative medicine therapies was evaluated using univariate and multivariate analysis.
RESULTS: The prevalence of alternative medicine use by prostate carcinoma patients responding to the survey was 43% (81 of 190 patients). No significant differences in alternative medicine use were observed between the patients who received brachytherapy alone (38%), those who underwent radical prostatectomy (40%), and those treated with combined brachytherapy and external beam radiation therapy (51%). Vitamins, prayer or other religious practices, and herbal medicines were the most commonly used therapies in these patients. Higher pretreatment Gleason scores were associated with a greater use of alternative medicine therapies on both multivariate and univariate analyses. Finally, using multivariate analysis, younger prostate carcinoma patients were more likely to use alternative medicine therapies than older patients.
CONCLUSIONS: Alternative medicine use is very prevalent among patients treated for localized prostate carcinoma. Because some of these treatments may have a potential biologic impact on tumor behavior and, consequently, on definitive or surrogate therapeutic endpoints, patients should be questioned carefully regarding alternative medicine use during routine tumor follow-up. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Year:  1999        PMID: 10594859

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Is it time for oncologists to modify their laissez-faire attitude toward alternative/complementary 'drug therapy'?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 2.  Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality.

Authors:  Joanne Barnes
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

3.  Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations.

Authors:  Marion M Lee; Jeffrey S Chang; Bradly Jacobs; Margaret R Wrensch
Journal:  Am J Public Health       Date:  2002-10       Impact factor: 9.308

Review 4.  Polypharmacy in older adults with cancer.

Authors:  Ronald J Maggiore; Cary P Gross; Arti Hurria
Journal:  Oncologist       Date:  2010-04-24

5.  Use of complementary and alternative medicine among men with prostate cancer in a rural setting.

Authors:  Susan Butler; Ashli Owen-Smith; Colleen DiIorio; Michael Goodman; Jonathan Liff; Kyle Steenland
Journal:  J Community Health       Date:  2011-12

Review 6.  Integrative medicine: complementary therapies and supplements.

Authors:  Barrie R Cassileth; Jyothirmai Gubili; K Simon Yeung
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

Review 7.  Nutraceuticals and prostate cancer prevention: a current review.

Authors:  Greg Trottier; Peter J Boström; Nathan Lawrentschuk; Neil E Fleshner
Journal:  Nat Rev Urol       Date:  2009-12-08       Impact factor: 14.432

8.  Complementary and alternative medicine use among newly diagnosed prostate cancer patients.

Authors:  Cara L McDermott; David K Blough; Catherine R Fedorenko; Neeraj K Arora; Steven B Zeliadt; Megan E Fairweather; Ingrid Oakley-Girvan; Stephen K Van Den Eeden; Scott D Ramsey
Journal:  Support Care Cancer       Date:  2010-12-01       Impact factor: 3.603

Review 9.  Complementary and alternative medicine in prostate cancer.

Authors:  J S Jacobson; A P Chetty
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

10.  Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Authors:  A Kolstad; T Risberg; Y Bremnes; T Wilsgaard; H Holte; O Klepp; O Mella; E Wist
Journal:  Support Care Cancer       Date:  2004-02-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.